Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

859 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Randomized double-blind prospective trial to evaluate the effects of sargramostim versus placebo in a moderate-dose fluorouracil, doxorubicin, and cyclophosphamide adjuvant chemotherapy program for stage II and III breast cancer.
Jones SE, Schottstaedt MW, Duncan LA, Kirby RL, Good RH, Mennel RG, George TK, Snyder DA, Watkins DL, Denham CA, Hoyes FA, Rubin AS. Jones SE, et al. J Clin Oncol. 1996 Nov;14(11):2976-83. doi: 10.1200/JCO.1996.14.11.2976. J Clin Oncol. 1996. PMID: 8918495 Clinical Trial.
Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer.
Jones SE, Savin MA, Holmes FA, O'Shaughnessy JA, Blum JL, Vukelja S, McIntyre KJ, Pippen JE, Bordelon JH, Kirby R, Sandbach J, Hyman WJ, Khandelwal P, Negron AG, Richards DA, Anthony SP, Mennel RG, Boehm KA, Meyer WG, Asmar L. Jones SE, et al. J Clin Oncol. 2006 Dec 1;24(34):5381-7. doi: 10.1200/JCO.2006.06.5391. J Clin Oncol. 2006. PMID: 17135639 Clinical Trial.
A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer.
Valero V, Jones SE, Von Hoff DD, Booser DJ, Mennel RG, Ravdin PM, Holmes FA, Rahman Z, Schottstaedt MW, Erban JK, Esparza-Guerra L, Earhart RH, Hortobagyi GN, Burris HA 3rd. Valero V, et al. Among authors: jones se. J Clin Oncol. 1998 Oct;16(10):3362-8. doi: 10.1200/JCO.1998.16.10.3362. J Clin Oncol. 1998. PMID: 9779713 Clinical Trial.
Randomized, double-blind, placebo-controlled trial to evaluate the hematopoietic growth factor PIXY321 after moderate-dose fluorouracil, doxorubicin, and cyclophosphamide in stage II and III breast cancer.
Jones SE, Khandelwal P, McIntyre K, Mennel R, Orr D, Kirby R, Agura E, Duncan L, Hyman W, Roque T, Regan D, Schuster M, Dimitrov N, Garrison L, Lange M. Jones SE, et al. J Clin Oncol. 1999 Oct;17(10):3025-32. doi: 10.1200/JCO.1999.17.10.3025. J Clin Oncol. 1999. PMID: 10506596 Clinical Trial.
Adjuvant chemotherapy with doxorubicin and cyclophosphamide in women with rapidly proliferating node-negative breast cancer.
Jones SE, Clark G, Koleszar S, Ethington G, Mennel R, Paulson S, Brooks B, Kerr R, Denham C, Savin M, Blum J, Kirby R, Stone M, Pippen J, George T, Orr D, Knox S, Grant M, Peters G, Savino D, Rietz C. Jones SE, et al. Clin Breast Cancer. 2002 Jun;3(2):147-52. doi: 10.3816/CBC.2002.n.019. Clin Breast Cancer. 2002. PMID: 12123539 Clinical Trial.
Low proliferative rate of invasive node-negative breast cancer predicts for a favorable outcome: a prospective evaluation of 669 patients.
Jones S, Clark G, Koleszar S, Ethington G, Mennel R, Paulson S, Brooks B, Kerr R, Denham C, Savin M, White C, Blum J, Kirby R, Stone M, Pippen J, Kitchens L, George T, Cooper B, Peters G, Knox S, Grant M, Cheek H, Jones R, Kuhn J, Lieberman Z, Savino D, Rietz C. Jones S, et al. Clin Breast Cancer. 2001 Jan;1(4):310-4; discussion 315-7. doi: 10.3816/CBC.2001.n.005. Clin Breast Cancer. 2001. PMID: 11899353
859 results